CN104418830A - Process for preparing (1S)-1,6-didehydro-1-[4-methoxyl-3-(trans-4- n-propyl cyclohexyl) methyl phenyl]-D-glucose - Google Patents

Process for preparing (1S)-1,6-didehydro-1-[4-methoxyl-3-(trans-4- n-propyl cyclohexyl) methyl phenyl]-D-glucose Download PDF

Info

Publication number
CN104418830A
CN104418830A CN201310409870.XA CN201310409870A CN104418830A CN 104418830 A CN104418830 A CN 104418830A CN 201310409870 A CN201310409870 A CN 201310409870A CN 104418830 A CN104418830 A CN 104418830A
Authority
CN
China
Prior art keywords
compound
acid
preparation
iii
converted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201310409870.XA
Other languages
Chinese (zh)
Inventor
赵桂龙
谢亚非
刘钰强
汪文锦
魏群超
王玉丽
吴疆
徐为人
汤立达
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tianjin Institute of Pharmaceutical Research Co Ltd
Original Assignee
Tianjin Institute of Pharmaceutical Research Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tianjin Institute of Pharmaceutical Research Co Ltd filed Critical Tianjin Institute of Pharmaceutical Research Co Ltd
Priority to CN201310409870.XA priority Critical patent/CN104418830A/en
Publication of CN104418830A publication Critical patent/CN104418830A/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/18—Acyclic radicals, substituted by carbocyclic rings

Abstract

The invention belongs to the technical field of medicines, and discloses a method for preparing a deoxy C-glucoside SGLT2 inhibitor DO capable of being used for preparing a medicine for treating type 2 diabetes mellitus. The method disclosed by the invention has the characteristics of short procedure and low cost, and is suitable for large-scale industrialization. The reaction formula is shown in the specification.

Description

(1S) preparation technology of-1,6-dideoxy-1-[4-methoxyl group-3-(trans-4-n-propyl cyclohexyl) aminomethyl phenyl]-D-Glucose
Technical field
The invention belongs to medical art, be specifically related to a kind of deoxidation C-glucosides class SGLT2 inhibitor that may be used for treating diabetes, more specifically relating to a kind of deoxidation C-glucosides class SGLT2 inhibitor containing cyclohexane structure can industrialized preparation method.
Background technology
The present inventor discloses compound (1S)-1,6-dideoxy-1-[4-methoxyl group-3-(trans-4-n-propyl cyclohexyl) aminomethyl phenyl]-D-Glucose (See Figure in CN201310016846.x.This compound label is DO herein) as Na +-glucose cotransporter 2 (sodium-dependent glucose cotransporter2, SGLT2) inhibitor, this compound may be used for the medicine preparing treatment diabetes B.
In further studying, the present inventor finds, the method being used for preparing Compound D O disclosed in CN201310016846.x is be raw material with the compound of the non-deoxidation in 6-position of its correspondence (as shown below), due to the complicated (Shao Hua of this raw material preparation itself, high Yunlong, Lou Yuanyuan, Wang Yuli, Liu Wei, Xu is people, Wang Jianwu, Zhao Guilong, soup Rieter, containing the design of the C-glucose glycoside SGLT2 inhibitor of trans cvclohexvl alkyl structure, synthesis and hypoglycemic activity are studied, organic chemistry, 2011, 31 (6), 836-842), thus its price is very expensive, in addition utilize its synthetic route step as raw material more, therefore this route is not suitable for suitability for industrialized production.
The invention discloses the new synthetic method of a kind of Compound D O, have easy and simple to handle, step is short, low cost and other advantages, is applicable to large-scale industrial production.
Summary of the invention
The novel synthesis of Compound D O of the present invention is as follows:
Each step reaction of the route of above-mentioned synthesis DO is as follows:
(1) the first step.
Compound I alkyl lithium reagents (as n-BuLi, t-BuLi or sec-BuLi) or MAGNESIUM METAL process, be converted into corresponding lithium aryl or aryl azoviolet, then reacts with Compound II per again, the adduct III-M obtained.
(2) second step.
III-M can obtain III with acid treatment in presence of methyl alcohol.Described acid is selected from various mineral acid, and some organic acid, as methylsulfonic acid, tosic acid, trifluoromethanesulfonic acid, trifluoroacetic acid etc.
(3) the 3rd steps.
Compound III-M and III all with reductive agent reduction under Lewis acid exists, can obtain product IV.Reductive agent is selected from Et 3siH, Lewis acid is selected from BF 3et 2o, AlCl 3, SnCl 2, SnCl 4, ZnCl 2, TMSOTf, preferred BF 3et 2o.
(4) the 4th steps.
Compound IV removes benzyl and obtains product D O.The condition of debenzylation is selected from: 1) trifluoromethanesulfonic acid/trifluoroacetic acid/dimethyl sulphide/meta-cresol/1，2-ethandithiol; 2) catalytic hydrogenation, catalyzer is selected from Pd/C and Pd (OH) 2, hydrogen source is selected from H 2, ammonium formiate, formic acid and tetrahydrobenzene.
Invention also provides the technique (as shown below) that a kind of crude product DO purifies.Be converted into compound V by crude product DO acylations, slough acyl group again after being purified by column chromatography and/recrystallization by compound V and obtain highly purified Compound D O.Wherein R is selected from Me, Et, Ph, p-methylphenyl, p-nitrophenyl etc.The condition of sloughing the acyl group in compound V comprises: 1) MOH/ protonic solvent/H 2o, MOH is wherein selected from NaOH, KOH, LiOH, and protonic solvent is selected from MeOH, EtOH, Virahol, propyl alcohol; 2) NaOR 1/ R 1oH, R 1be selected from Me, EtOH, n-Pr and i-Pr; 3) R 2nH 2/ protonic solvent, wherein R 2be selected from H, Me and Et, protonic solvent is selected from MeOH, EtOH, Virahol, n-propyl alcohol, the trimethyl carbinol.
Embodiment
Below in conjunction with embodiment, the present invention is further illustrated.It should be noted that, following embodiment be only for illustration of, and not for limiting the present invention.The various changes that those skilled in the art's training centre according to the present invention is made all should within the protection domain required by the application's claim.
The synthesis of embodiment 1 compound III-M
Add the THF of 3.25g (10mmol) Compound I and 30mL drying in the dry round-bottomed flask of a 250mL, add magneton, with the sealing of rubber cork after nitrogen purging.Flask is placed in liquid nitrogen-ethanol system and is cooled to-78 DEG C, starts induction stirring.The n-Butyl Lithium of 6.25mL (10mmol) 1.6M is slowly dripped with syringe, continue at such a temperature after dropwising to stir half an hour, then slowly drip by syringe the solution that THF that 4.33g (10mmol) II is dissolved in 20mL drying makes.Reaction mixture continues stirring 1 hour at such a temperature, is then slowly warming up to room temperature reaction 1 hour.Reaction mixture is poured in 400mL frozen water, stirs, uses saturated NaHCO 3solution regulates the dichloromethane extraction of pH=4-6,100mL × 3.Merge organic phase, weak brine washs, and anhydrous sodium sulfate drying, on a rotary evaporator evaporate to dryness, resistates is the crude product of III-M, ESI-MS, m/z=696 ([M+NH 4] +).This crude product, without purifying, is directly used in next step reaction.
The synthesis of embodiment 2 compound III
Add the THF of 3.25g (10mmol) Compound I, 0.29g (12mmol) MAGNESIUM METAL and 20mL drying in the dry round-bottomed flask of a 100mL, add magneton, stirred at ambient temperature.Add a granule iodine, then the whole flask hot water heating of 65 DEG C, causes until react and is exhausted by much part metals magnesium.Flask ice-water bath is cooled, slowly drips by dropping funnel the solution that THF that 4.33g (10mmol) II is dissolved in 20mL drying makes.After dropwising, reaction mixture continues stirring 1 hour at such a temperature.Under ice-water bath cooling, slowly drip 2.88g (30mmol) methylsulfonic acid by dropping funnel and be dissolved in the solution that 20mL methyl alcohol makes, dropwise rear room temperature for overnight.Reaction mixture is poured in 200mL frozen water, stirs half an hour, uses saturated NaHCO 3solution regulates the dichloromethane extraction of pH=4-6,50mL × 3.Merge organic phase, weak brine washs, and anhydrous sodium sulfate drying, on a rotary evaporator evaporate to dryness, resistates is the crude product of III, ESI-MS, m/z=710 ([M+NH 4] +).This crude product, without purifying, is directly used in next step reaction.
The synthesis of embodiment 3 compound IV
The crude product of compound III-M prepared by embodiment 1 is dissolved in the methylene dichloride of 50mL drying in the round-bottomed flask of 250mL, adds 2.33g (20mmol) Et 3siH, stirs under-30 DEG C of coolings.The solution that methylene dichloride that 1.42g (10mmol) boron trifluoride diethyl etherate is dissolved in 5mL drying makes slowly is dripped by dropping funnel.After dropwising, reaction mixture continues stirring and is then warming up to room temperature gradually in 1 hour at-30 DEG C, and at room temperature continues stirring 5 hours, and TLC shows reaction to be completed.In compound of reaction, carefully add 20mL saturated sodium bicarbonate solution, be poured in 200mL frozen water after continuing to stir half an hour, stir, the dichloromethane extraction of 100mL × 3.Merge organic phase, weak brine washs, anhydrous sodium sulfate drying, on a rotary evaporator evaporate to dryness, and resistates column chromatography purification, obtains the sterling of IV, white solid, fusing point 105-106.5 DEG C, 1h NMR (DMSO-d 6, 400MHz), δ 7.13-7.34 (m, 15H), 6.91-6.93 (m, 2H), 6.81 (d, 1H, J=8.4Hz), 4.84-4.93 (m, 3H), 4.69 (d, 1H, J=10.8Hz), 4.33 (d, 1H, J=10.4Hz), 4.14 (d, 1H, J=9.2Hz), 3.82 (d, 1H, J=10.4Hz), 3.79 (s, 3H), 3.74 (t, 1H, J=9.2Hz), 3.49-3.53 (m, 2H), 3.30 (t, 1H, J=9.2Hz), 2.56 (dd, 1H, J=6.8Hz and12.8Hz), 2.38 (dd, 1H, J=3.4Hz and13.0Hz), 1.62-1.64 (m, 4H), 1.32 (d, 3H, J=6.0Hz), 1.21-1.28 (m, 3H), 1.07-1.13 (m, 3H), 0.87-0.97 (m, 2H), 0.83 (t, 3H, J=7.4Hz), 0.72-0.77 (m, 2H).
The synthesis of embodiment 4 compound IV
The crude product of compound III prepared by embodiment 2 is dissolved in the methylene dichloride of 50mL drying in the round-bottomed flask of 250mL, adds 2.33g (20mmol) Et 3siH, stirs under-30 DEG C of coolings.The solution that methylene dichloride that 1.42g (10mmol) boron trifluoride diethyl etherate is dissolved in 5mL drying makes slowly is dripped by dropping funnel.After dropwising, reaction mixture continues stirring and is then warming up to room temperature gradually in 1 hour at-30 DEG C, and at room temperature continues stirring 5 hours, and TLC shows reaction to be completed.In compound of reaction, carefully add 20mL saturated sodium bicarbonate solution, be poured in 200mL frozen water after continuing to stir half an hour, stir, the dichloromethane extraction of 100mL × 3.Merge organic phase, weak brine washs, anhydrous sodium sulfate drying, on a rotary evaporator evaporate to dryness, and resistates column chromatography purification, obtains the sterling of IV, white solid, fusing point 105-106.5 DEG C, 1h NMR (DMSO-d 6, 400MHz), δ 7.13-7.34 (m, 15H), 6.91-6.93 (m, 2H), 6.81 (d, 1H, J=8.4Hz), 4.84-4.93 (m, 3H), 4.69 (d, 1H, J=10.8Hz), 4.33 (d, 1H, J=10.4Hz), 4.14 (d, 1H, J=9.2Hz), 3.82 (d, 1H, J=10.4Hz), 3.79 (s, 3H), 3.74 (t, 1H, J=9.2Hz), 3.49-3.53 (m, 2H), 3.30 (t, 1H, J=9.2Hz), 2.56 (dd, 1H, J=6.8Hz and12.8Hz), 2.38 (dd, 1H, J=3.4Hz and13.0Hz), 1.62-1.64 (m, 4H), 1.32 (d, 3H, J=6.0Hz), 1.21-1.28 (m, 3H), 1.07-1.13 (m, 3H), 0.87-0.97 (m, 2H), 0.83 (t, 3H, J=7.4Hz), 0.72-0.77 (m, 2H).
The synthesis of embodiment 5 Compound D O
3.31g (5mmol) compound IV is dissolved in 20mL THF, and add 0.5g10%Pd/C, under room temperature, catalytic hydrogenation is spent the night.Reaction mixture suction filtration, filtrate is evaporate to dryness on a rotary evaporator, and resistates obtains a white foam solid after short column column chromatography purification, is DO.White foam solid. 1H NMR(DMSO-d 6,400MHz),δ7.07(dd,1H,J=2.0Hz and8.4Hz),6.97(d,1H,J=2.0Hz),6.84(d,1H,J=8.4Hz),4.91(d,1H,J=5.6Hz),4.84(d,1H,J=4.4Hz),4.62(d,1H,J=5.2Hz),3.91(d,1H,J=9.2Hz),3.73(s,3H),3.12-3.28(m,3H),2.89-2.94(m,1H),2.44(dd,1H,J=6.8Hz and12.8Hz),2.35(dd,1H,J=7.2Hzand12.8Hz),1.59-1.67(m,4H),1.39(s,1H),1.23-1.29(m,3H),1.07-1.15(m,5H),0.88-0.96(m,7H); 13C NMR(DMSO-d 6,100MHz),δ156.54,131.81,129.98,127.77,126.25,109.89,81.21,78.20,75.64,74.77,55.30,39.19,38.09,37.40,36.85,32.71,32.67,32.61,19.42,18.24,14.19.HR-ESI-MS,m/z=410.2916([M+NH 4] +,C 23H 40NO 5,410.2906),415.2467([M+Na] +,C 23H 36NaO 5,415.2460).
The synthesis of embodiment 6 Compound D O
3.31g (5mmol) compound IV is dissolved in 20mL THF, adds 0.20g Pd (OH) 2, under room temperature, catalytic hydrogenation is spent the night.Reaction mixture suction filtration, filtrate is evaporate to dryness on a rotary evaporator, and resistates obtains a white foam solid after short column column chromatography purification, is DO.White foam solid.Structural characterization data are consistent with embodiment 5.
The synthesis of embodiment 7 Compound D O
3.31g (5mmol) compound IV is dissolved in the mixing solutions of 20mL THF and 10mL methyl alcohol, adds 10g HCO 2nH 4, room temperature for overnight.Reaction mixture suction filtration, filtrate is evaporate to dryness on a rotary evaporator, and resistates obtains a white foam solid after short column column chromatography purification, is DO.White foam solid.Structural characterization data are consistent with embodiment 5.
The synthesis of embodiment 8 Compound D O
3.31g (5mmol) compound IV is dissolved in 20mL THF, adds 10mL tetrahydrobenzene, room temperature for overnight.Reaction mixture suction filtration, filtrate is evaporate to dryness on a rotary evaporator, and resistates obtains a white foam solid after short column column chromatography purification, is DO.White foam solid.Structural characterization data are consistent with embodiment 5.
The synthesis of embodiment 9 Compound D O
3.31g (5mmol) compound IV is dissolved in the mixed solvent be made up of 1.5mL trifluoroacetic acid, 9mL dimethyl thioether, 2.4mL m-methyl phenol and 0.6mL dithioglycol, is cooled to-15 DEG C.Slowly drip 3mL trifluoromethanesulfonic acid.Slowly be raised to room temperature after adding, then continue stirring 1 hour, TLC shows reaction to be completed.Be poured into after reaction mixture is slightly cold in 200mL frozen water, stir, the extraction into ethyl acetate of 50mL × 3.Merge organic phase, weak brine washs, and anhydrous sodium sulfate drying, on a rotary evaporator evaporate to dryness, resistates obtains a white foam solid after short column chromatography purifying, is DO.Structural characterization data are consistent with embodiment 5.
Embodiment 10 is by DO synthetic compound V-1
1.18g (3mmol) Compound D O crude product is dissolved in 10mL pyridine, adds 0.2g DMAP, stirs under ice-water bath cooling, 7mL acetic anhydride is slowly dripped by dropping funnel, after dropwising, reaction mixture at room temperature stirs and spends the night, and TLC shows reaction to be completed.Reaction mixture is poured in 100mL frozen water, stirs, the extraction into ethyl acetate of 50mL × 3.Merge organic phase, respectively with the hydrochloric acid of 100mL2% and weak brine washing, anhydrous sodium sulfate drying, on a rotary evaporator evaporate to dryness, resistates obtains the sterling of V-1 through short column chromatography purifying, white foam solid. 1H NMR(DMSO-d6,400MHz),δ7.13(dd,1H,J=2.0Hz and8.4Hz),6.98(d,1H,J=2.0Hz),6.87(d,1H,J=8.4Hz),5.24(t,1H,J=9.6Hz),4.99(t.1H.J=9.6Hz),4.81(t,1H,J=9.6Hz),4.48(d,1H,J=10.0Hz),3.81(dd,1H,J=6.4Hz and9.6Hz),3.73(s,3H),2.38-2.40(m,2H),2.03(s,3H),1.92(s,3H),1.70(s,3H),1.64-1.66(m,2H),1.51-1.57(m,2H),1.38-1.45(m,1H),1.23-1.28(m,3H),1.08-1.12(m,6H),0.76-0.91(m,8H).
Embodiment 11 is by DO synthetic compound V-2
1.18g (3mmol) Compound D O crude product is dissolved in 10mL pyridine, add 0.2g DMAP, stir under ice-water bath cooling, 2.11g (15mmol) Benzoyl chloride is slowly dripped by dropping funnel, after dropwising, reaction mixture at room temperature stirs and spends the night, and TLC shows reaction to be completed.Reaction mixture is poured in 100mL frozen water, stirs, the extraction into ethyl acetate of 50mL × 3.Merge organic phase, respectively with the hydrochloric acid of 100mL2% and weak brine washing, anhydrous sodium sulfate drying, on a rotary evaporator evaporate to dryness, resistates obtains the sterling of V-2 through short column chromatography purifying, white solid, MS, m/z=705 ([M+H] +).
Embodiment 12 is by V-1 synthetic compound DO
1.04g (2mmol) compound V-1 is dissolved in 10mL methyl alcohol, stirred at ambient temperature, then the NaOH solution adding 1mL30%, then temperature rising reflux half an hour, and TLC shows reaction to be completed.Be poured into after reaction mixture is slightly cold in 50mL frozen water, stir, regulate pH=7 with hydrochloric acid, with the extraction into ethyl acetate of 50mL × 3.Merge organic phase, weak brine washs, and anhydrous sodium sulfate drying, on a rotary evaporator evaporate to dryness, resistates, through too short purification by silica gel column chromatography, obtains the sterling of DO, and structural characterization data are consistent with embodiment 4.
Embodiment 13 is by V-1 synthetic compound DO
0.2g sodium Metal 99.5 joins in 20mL anhydrous methanol, stirred at ambient temperature, until sodium Metal 99.5 disappears, then adds 1.04g (2mmol) compound V-1, continues stirring 5 hours, and now TLC display reaction completes.Add dry storng-acid cation exchange resin 2g, room temperature for overnight, until pH=7.Suction filtration removing resin, filtrate is evaporate to dryness on a rotary evaporator, and the resistates obtained, through too short purification by silica gel column chromatography, obtains the sterling of DO, and structural characterization data are consistent with embodiment 4.
Embodiment 14 is by V-2 synthetic compound DO
1.41g (2mmol) compound V-2 is dissolved in the saturated NH of 20mL 3in/methyl alcohol, stir and spend the night at 50 DEG C, TLC shows reaction to be completed.Be poured into after compound of reaction is slightly cold in 300mL frozen water, stir, the extraction into ethyl acetate of 50mL × 3.Merge organic phase, weak brine washs, and anhydrous sodium sulfate drying, on a rotary evaporator evaporate to dryness, resistates, through too short purification by silica gel column chromatography, obtains the sterling of DO, and structural characterization data are consistent with embodiment 4.

Claims (12)

1. prepare a method of Compound D O, it is characterized in that, comprise the steps:
(1) Compound I alkyl lithium reagents or MAGNESIUM METAL process, is converted into corresponding lithium aryl or aryl azoviolet; Then react with Compound II per again, obtain adduct III-M;
(2) compound III-M obtains compound III under methyl alcohol and acid treatment;
(3) compound III reduction under Lewis acid exists, obtains product IV;
(4) compound IV is sloughed benzyl and is converted into Compound D O.
2. preparation method as claimed in claim 1, the alkyl lithium reagents described in step (1) is selected from n-BuLi, t-BuLi or sec-BuLi.
3. preparation method as claimed in claim 1, the acid described in step (2) is selected from mineral acid, methylsulfonic acid, tosic acid, trifluoromethanesulfonic acid or trifluoroacetic acid.
4. preparation method as claimed in claim 1, the reductive condition described in step (3) selects Et for selecting reductive agent 3siH; Described Lewis acid is selected from BF 3et 2o, AlCl 3, SnCl 2, SnCl 4, ZnCl 2, TMSOTf.
5. preparation method as claimed in claim 1, the condition of the debenzylation described in step (4) is selected from: 1) trifluoromethanesulfonic acid/trifluoroacetic acid/dimethyl sulphide/meta-cresol/1，2-ethandithiol; 2) catalytic hydrogenation; Catalyzer is selected from Pd/C and Pd (OH) 2, hydrogen source is selected from H 2, ammonium formiate, formic acid or tetrahydrobenzene.
6. the compound of formula IV,
7. the compound of formula III,
8. the compound of formula III-M,
9. preparation method as claimed in claim 1, also protects the purification step of Compound D O,
It is characterized in that,
(1) Compound D O acylations is converted into compound V;
(2) compound V sloughs acyl group in the basic conditions and is converted into DO;
Wherein, R is methyl, ethyl, propyl group, phenyl, p-methylphenyl, p-nitrophenyl.
10. preparation method as claimed in claim 9, in described purification step (1) acylting agent be selected from diacetyl oxide, Acetyl Chloride 98Min., propionyl chloride, Benzoyl chloride, to methyl benzoyl chloride, paranitrobenzoyl chloride.
11. preparation methods as claimed in claim 9, described purification step (2) neutral and alkali reaction conditions is selected from: 1) MOH/ protonic solvent/H 2o, MOH is wherein selected from NaOH, KOH, LiOH, and described protonic solvent is selected from MeOH, EtOH, Virahol, propyl alcohol; 2) NaOR 1/ R 1oH, R 1be selected from Me, EtOH, n-Pr and i-Pr; 3) R 2nH 2/ protonic solvent, wherein R 2be selected from H, Me and Et, described protonic solvent is selected from MeOH, EtOH, Virahol, n-propyl alcohol, the trimethyl carbinol.
The compound of 12. formula V,
Wherein, R is selected from Me, Et, Ph, p-methylphenyl and p-nitrophenyl.
CN201310409870.XA 2013-09-10 2013-09-10 Process for preparing (1S)-1,6-didehydro-1-[4-methoxyl-3-(trans-4- n-propyl cyclohexyl) methyl phenyl]-D-glucose Pending CN104418830A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201310409870.XA CN104418830A (en) 2013-09-10 2013-09-10 Process for preparing (1S)-1,6-didehydro-1-[4-methoxyl-3-(trans-4- n-propyl cyclohexyl) methyl phenyl]-D-glucose

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201310409870.XA CN104418830A (en) 2013-09-10 2013-09-10 Process for preparing (1S)-1,6-didehydro-1-[4-methoxyl-3-(trans-4- n-propyl cyclohexyl) methyl phenyl]-D-glucose

Publications (1)

Publication Number Publication Date
CN104418830A true CN104418830A (en) 2015-03-18

Family

ID=52969033

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201310409870.XA Pending CN104418830A (en) 2013-09-10 2013-09-10 Process for preparing (1S)-1,6-didehydro-1-[4-methoxyl-3-(trans-4- n-propyl cyclohexyl) methyl phenyl]-D-glucose

Country Status (1)

Country Link
CN (1) CN104418830A (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070027092A1 (en) * 2005-07-27 2007-02-01 Frank Himmelsbach Glucopyranosyl-substituted ((hetero)cycloalkylethynyl-benzyl)-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
CN102134226A (en) * 2010-01-26 2011-07-27 天津药物研究院 Phenyl C-glucoside derivatives, preparation method and use thereof
CN102146066A (en) * 2010-02-05 2011-08-10 天津药物研究院 C-glucoside derivatives containing saturated six-membered ring as well as preparation method and application thereof
CN102516215A (en) * 2011-12-12 2012-06-27 天津药物研究院 Preparation method of C-glucoside containing saturated cyclohexane structure
CN103058972A (en) * 2013-01-17 2013-04-24 天津药物研究院 Phenyl C-glucoside derivatives containing cyclohexane structure as well as preparation method and application thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070027092A1 (en) * 2005-07-27 2007-02-01 Frank Himmelsbach Glucopyranosyl-substituted ((hetero)cycloalkylethynyl-benzyl)-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
CN102134226A (en) * 2010-01-26 2011-07-27 天津药物研究院 Phenyl C-glucoside derivatives, preparation method and use thereof
CN102146066A (en) * 2010-02-05 2011-08-10 天津药物研究院 C-glucoside derivatives containing saturated six-membered ring as well as preparation method and application thereof
CN102516215A (en) * 2011-12-12 2012-06-27 天津药物研究院 Preparation method of C-glucoside containing saturated cyclohexane structure
CN103058972A (en) * 2013-01-17 2013-04-24 天津药物研究院 Phenyl C-glucoside derivatives containing cyclohexane structure as well as preparation method and application thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
SHUO ZHANG等: "Design, synthesis and biological activity of cyclohexane-bearing C-glucoside derivatives as SGLT2 inhibitors", 《CHINESE CHEMICAL LETTERS》, vol. 24, 11 April 2013 (2013-04-11), pages 431 - 11 *
刘懋勤: "某些开链糖核苷衍生物的脱苄基反应", 《医药工业》, vol. 17, no. 10, 31 October 1986 (1986-10-31) *
邵华等: "含反式环己烷结构的C-葡萄糖苷类SGLT2 抑制剂的设计、合成与降血糖活性研究", 《有机化学》, vol. 31, no. 6, 30 June 2011 (2011-06-30) *

Similar Documents

Publication Publication Date Title
JP6144686B2 (en) Process for preparing β-C-aryl glucoside
CN111925381B (en) Synthesis method of baroxavir key intermediate
CN102127092A (en) Preparation of Everolimus
CN108358857A (en) The synthetic method of 1- alkyl -5- aryloxy group -1,2,3- triazole compounds
CN104098536B (en) The synthetic method of a kind of deoxidation C-glucosides class SGLT2 inhibitor and intermediate product thereof
CN104557572A (en) Levalbuterol intermediate and levalbuterol hydrochloride synthesis method
CN103087019B (en) Preparation method of tasimelteon
CN103833570B (en) Synthesis method of oseltamivir
CN105330581A (en) Preparation method for (S)-oxiracetam
JP5646706B2 (en) Method for producing C-glycoside derivative
CN101289439B (en) Process for preparing arabglycal
CN104072398A (en) Method for synthesizing ezetimibe
CN101575298B (en) Method for preparing chiral medicinal intermediate 2-amido-1-phenylethylalcohol
CN102964346A (en) Preparation method of (S, S)-octahydro-6H-pyrrolo[3, 4-b]pyridine
CN104418830A (en) Process for preparing (1S)-1,6-didehydro-1-[4-methoxyl-3-(trans-4- n-propyl cyclohexyl) methyl phenyl]-D-glucose
CN103288890A (en) Novel method for preparing 3-O-benzyl-1, 2-O-isopropylidene-alpha-L-furan idose
CN103787968B (en) The preparation method of compound
CN110698467A (en) Synthetic method of engagliflozin
CN107345140B (en) Liquid crystal compound with isobutyl negative dielectric anisotropy and application thereof
CN107345141B (en) Liquid crystal compound with negative dielectric anisotropy of isoamyl and application thereof
CN104418847A (en) Process for preparing 4-(6-deoxidized-beta-D-glucopyranose)-2-[5-(4-fluorophenyl) thiophene-2-methyl]-1-methyl benzol
CN101503625B (en) Preparation method of 1,2-diaryl ethine liquid crystal
CN105481715B (en) A kind of camphor schiff bases and its preparation method and application
CN109265385B (en) Synthesis process of chiral catalyst
EP2896642B1 (en) Method for producing polyalkylene glycol derivative with narrow molecular weight distribution, and acetal-group containing alcohol compound for use therein and alkali metal salt thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20150318